Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC PET Study in Bipolar Depression
NCT03730064Phase 1Completed
- Start
- Nov 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of acetylcysteine in bipolar disorder (BD). Primary endpoint: Montgomery Asberg Depression Rating Scale at 6 weeks. Started Nov 2018; status: completed.
02
Drugs
acetylcysteine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT03730064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03730064.